Skip to content

Small Doses of Dexmedetomidine for Emergence Agitation

Influence of Small Doses Dexmedetomidine to the Elderly Patients' Emergence Agitation

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02169843
Enrollment
80
Registered
2014-06-23
Start date
2014-05-31
Completion date
2014-10-31
Last updated
2014-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence Agitation

Keywords

Dexmedetomidine,, agitation,, AFPS,, NRS,, mean arterial pressure, heart rate(HR)

Brief summary

Dexmedetomidine Hydrochloride is a kind of high selectivity alpha 2 agonists adrenaline, can inhibit the activity of sympathetic nerve, and reduce the adverse effects of stress reaction in anesthesia recovery period.Literatures have been reported that Dex can reduce the rate of emergence agitation of children and adults,especially in elderly patients(\>64 years) after using sevoflurane anesthesia.

Interventions

DRUGSevoflurane

inhale Sevoflurane

DRUGDexmedetomidine

intravenous pumping Dexmedetomidine 0.2µg/kg/h

DRUGPlacebo(for Dexmedetomidine)

normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h

Sponsors

Tang-Du Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. obtain informed consent; 2. patients whose selective under general anesthesia colorectal cancer or esophageal cancer radical operation time \> 2h; 3. the American society of anesthesiologists (ASA) class I-II; 4. age\>64 years old; 5. BMI\<28kg/㎡;

Exclusion criteria

1. systolic pressure≥180mm Hg or\<90mm Hg, diastolic pressure≥110mm Hg or\< 60mm Hg; 2. serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections; 3. patients with difficult airway (such as Mallampati airway class III, airway abnormalities, etc.) 4. HR\<50times/min 5. a history of mental illness or a long history of taking medicine of psychiatric drugs and chronic analgesics 6. a history of alcoholism 7. diseases of the neuromuscular 8. a tendency to malignant hyperthermia 9. allergy to test drugs or have other contraindications 10. participated in other clinical drug researches over the past 30 days

Design outcomes

Primary

MeasureTime frameDescription
evaluation of agitationthe duration of PACU room stay,expect 30 minutesstay in the PACU room after operation,measure the score of Aono's four-point scale(AFPS) every two minutes.
evaluation of painthe duration of PACU room stay,expect 30 minutesstay in the PACU room after operation,measure the score of numeric rating scale(NRS) every two minutes.
the amount of drugsthe duration of hospital stay,expect 5 weekswhen stay in the hospital,measure the total doses of Nalbuphine and Fentanyl using
number of agitationthe duration of hospital stay,expect 5 weekswhen stay in the hospital, measure the number of agitation.

Secondary

MeasureTime frameDescription
the mean arterial pressurefrom the beginning of induction to skin closure, up to 1 hourmeasure the mean arterial pressure at 6 time points including after pump injection of Dexmedetomidine or normal saline 10 minutes, 20 minutes,30 minutes,before pulling out the endotracheal tube,at the time of pulling out the endotracheal tube,and after pulling out the endotracheal tube 5 minutes
heart ratefrom the beginning of induction to skin closure, up to 1 hourmeasure the heart rate at 6 time points including after pump injection of Dexmedetomidine or normal saline 10 minutes, 20 minutes,30 minutes,before pulling out the endotracheal tube,at the time of pulling out the endotracheal tube,and after pulling out the endotracheal tube 5 minutes

Countries

China

Contacts

Primary ContactMeiyan Sun
smyszdlz@126.com15353575016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026